TOR1AIP2

Across TCGA pan-cancer cohorts, TOR1AIP2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TOR1AIP2 data layer compared with 26 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher TOR1AIP2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated TOR1AIP2 expression acts as an unfavorable survival marker, although some lineages such as LUAD and GBM show a favorable association.

LSCC, HNSC, and CCRCC are the cancer types where TOR1AIP2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Tertile	All	0.512	0.809	.007	27	view →
HNSC	OS	Median	All	0.499	0.979	.020	24	view →
CCRCC	OS	Median	All	0.668	1.000	.013	12	view →
LUAD	OS	Median	III,IV	0.773	0.248	.011	9	view →
GBM	OS	Quartile	All	0.676	0.380	.017	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TOR1AIP2–LSCC (DFS)

Open the LSCC breakdown →